tiprankstipranks
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
US Market

Arcturus Therapeutics (ARCT) Stock Price & Analysis

1,398 Followers

ARCT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$17.52 - $45.00
Previous Close$31.89
Volume131.20K
Average Volume (3M)557.04K
Market Cap
$852.22M
Enterprise Value$592.76M
Total Cash (Recent Filing)$292.00M
Total Debt (Recent Filing)$25.91M
Price to Earnings (P/E)
Beta1.93
Aug 05, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding26,931,826
10 Day Avg. Volume813,500
30 Day Avg. Volume557,042
Standard Deviation0.32
R-Squared0.20
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.08
Price to Sales (P/S)25.58
Price to Cash Flow (P/CF)-340.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.50
Enterprise Value/Gross Profit3.55
Enterprise Value/Ebitda-23.78
Forecast
Price Target Upside157.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say
Drug Development ProgressInitial cystic fibrosis data from Arcturus Therapeutics shows promising results, with a 4% improvement in lung function, indicating the company's strong position in the competitive landscape for cystic fibrosis treatments.
Financial PerformanceArcturus Therapeutics' financial outlook is bolstered by the anticipated launch of the first self-amplifying mRNA COVID-19 vaccine in Japan, with manufacturing and commercial milestones expected to drive future earnings growth.
Strategic CollaborationsArcturus Therapeutics' strategic collaboration with Achilles Therapeutics to develop personalized cancer vaccines leverages its mRNA platform, aligning with the industry's growing interest in individualized treatments for cancer.
Bears Say
Health PolicyVoluntary and non-subsidized vaccinations for individuals under 65 could lead to lower than anticipated uptake rates.
Market DemandAnalyst's skepticism surrounds Japan's likelihood to place substantial orders for Kostaive, potentially limiting the product's market penetration.
Product EfficacyLack of data suggests Arcturus' non-vaccine agents may not produce enough protein sustainably to rival competitive treatments.
---

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

ARCT FAQ

What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $17.52 and its highest was $45.00 in the past 12 months.
    What is Arcturus Therapeutics’s market cap?
    Currently, no data Available
    When is Arcturus Therapeutics’s upcoming earnings report date?
    Arcturus Therapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 54 days.
      How were Arcturus Therapeutics’s earnings last quarter?
      Arcturus Therapeutics released its earnings results on May 08, 2024. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.234 by $0.234.
        Is Arcturus Therapeutics overvalued?
        According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Arcturus Therapeutics pay dividends?
          Arcturus Therapeutics does not currently pay dividends.
          What is Arcturus Therapeutics’s EPS estimate?
          Arcturus Therapeutics’s EPS estimate is -$1.53.
            How many shares outstanding does Arcturus Therapeutics have?
            Arcturus Therapeutics has 26,931,826 shares outstanding.
              What happened to Arcturus Therapeutics’s price movement after its last earnings report?
              Arcturus Therapeutics reported an EPS of -$1 in its last earnings report, beating expectations of -$1.234. Following the earnings report the stock price went down -1.544%.
                Which hedge fund is a major shareholder of Arcturus Therapeutics?
                Among the largest hedge funds holding Arcturus Therapeutics’s share is ARK Investment Management LLC. It holds Arcturus Therapeutics’s shares valued at 57M.
                  ---

                  Company Description

                  Arcturus Therapeutics

                  Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
                  ---

                  ARCT Company Deck

                  ---

                  ARCT Earnings Call

                  Q1 2024
                  0:00 / 0:00
                  ---

                  ARCT Stock 12 Month Forecast

                  Average Price Target

                  $82.60
                  ▲(157.24% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","141":"$141","48.75":"$48.8","79.5":"$79.5","110.25":"$110.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$82.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,48.75,79.5,110.25,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.82,40.14153846153846,48.463076923076926,56.78461538461539,65.10615384615386,73.42769230769233,81.74923076923078,90.07076923076923,98.3923076923077,106.71384615384616,115.03538461538463,123.3569230769231,131.67846153846156,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.82,35.72615384615385,39.63230769230769,43.53846153846154,47.44461538461538,51.35076923076923,55.25692307692307,59.16307692307692,63.06923076923077,66.97538461538461,70.88153846153847,74.78769230769231,78.69384615384615,{"y":82.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.82,33.06461538461539,34.30923076923077,35.55384615384615,36.79846153846154,38.043076923076924,39.28769230769231,40.5323076923077,41.776923076923076,43.02153846153846,44.26615384615385,45.51076923076923,46.755384615384614,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.49,"date":1686268800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.36,"date":1688688000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":32.15,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.58,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.87,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.23,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.72,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.73,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.97,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.27,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.82,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Moderna
                  Ionis Pharmaceuticals
                  Arrowhead Pharmaceuticals
                  Viking Therapeutics

                  Best Analysts Covering ARCT

                  1 Year
                  Ed ArceH.C. Wainwright
                  1 Year Success Rate
                  9/10 ratings generated profit
                  90%
                  1 Year Average Return
                  +32.28%
                  reiterated a buy rating 3 months ago
                  Copying Ed Arce's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +32.28% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis